Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679069 | 1.00 | TRPV1 (0.59) | TRPV1EPHX2NPY5RKDM4EALDH1A1 | |
| SCHEMBL2724621 | 0.90 | TRPV1 (0.62) | TRPV1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2726587 | 0.89 | TRPV1 (0.56) | TRPV1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL31679062 | 0.89 | TRPV1 (0.56) | TRPV1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL2725222 | 0.88 | TRPV1 (0.66) | TRPV1EPHX2ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL31679061 | 0.88 | TRPV1 (0.66) | TRPV1EPHX2ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL17310439 | 0.87 | TRPV1 (0.47) | TRPV1NPY5RKDM4EMAPT | |
| SCHEMBL2723627 | 0.86 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL2723517 | 0.86 | TRPV1 (0.58) | TRPV1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL2724882 | 0.86 | TRPV1 (0.58) | TRPV1ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189303-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2024-06-13 | — | — | US | claimed |
| EP-3393462-B1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | UNIV ARIZONA (US) | 2023-02-01 | — | — | EP | claimed |
| US-20210069184-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2021-03-11 | — | — | US | claimed |
| US-20190192508-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2019-06-27 | — | — | US | claimed |
| US-20190008865-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2019-01-10 | — | — | US | claimed |
| US-10137123-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2018-11-27 | — | — | US | claimed |
| EP-3393462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | Arizona Board of Regents on behalf of the University of Arizona (US) | 2018-10-31 | — | — | EP | claimed |
| US-20170231982-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2017-08-17 | — | — | US | claimed |
| WO-2017112693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT, AMELIORATION, AND PREVENTION OF ANESTHESIA-INDUCED HYPOTHERMIA | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-29 | — | — | WO | claimed |
| US-20150352105-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-12-10 | — | — | US | claimed |
| US-9084786-B2 | Methods and compositions for prevention and treatmentof cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2015-07-21 | — | — | US | claimed |
| US-20130274271-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENTOF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII (US) | 2013-10-17 | — | — | US | claimed |
| EP-2635281-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | University Of Hawaii (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061505-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII (US) | 2012-05-10 | — | — | WO | claimed |
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-06-14 | — | — | US | claimed |
| JP-2007509915-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682141-A1 | 4-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-26 | — | — | EP | claimed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | claimed |
| US-12186314-B2 | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2005051390-A1 | E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135423-A1 | E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain | OPRL1, HVCN1, TRPV1 | TRPV1 3/4885EPHX2 785/4885NPY5R 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.